United States: Patent-Eligibility Of hESC Challenged

Now that the U.S. Supreme Court has determined that isolated, naturally-occurring genes are not patent-eligible (see, Ass'n. for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. __ (2013))("Myriad"), Consumer Watchdog ("CW", formerly known as The Foundation for Taxpayer and Consumer Rights, a self-described public charity dedicated to provide a voice for taxpayers and consumers) has asked the Federal Circuit to apply the holding of Myriad to in vitro cultured, human embryonic stem cell cultures and deem them patent-ineligible for failing to satisfy 35 U.S.C. § 101. Consumer Watchdog v. Wisconsin Alumni Research Foundation, No. 13-1377 (Fed. Cir. 2013).

Reexamination of U.S. Patent No. 7,029,913

CW's challenge is contained in an appeal from a Decision of the USPTO's Board of Patent Appeals ("Board") in inter partes reexamination No. 95/000,154, which confirmed the patentability of claims 1-3 of U.S. Patent No. 7,029,913 (the '913 Patent) entitled "Primate Embryonic Stem Cells". The '913 Patent issued on April 18, 2006 naming Dr. James A. Thomson of the University of Wisconsin as the sole inventor. The '913 Patent is assigned to Appellee Wisconsin Alumni Research Foundation ("WARF").

In the reexamination proceeding itself, Appellant CW only challenged the novelty and non-obviousness of the claims. The Board determined that the claims were novel because the cited prior art neither disclosed nor enabled using feeder cells to isolate human embryonic stem cells ("hESCs"). The Board also determined that the evidence of record supported a finding of non-obviousness because one of skill in the art would not have known how to identify and select hESCs during the stem cell derivation process.

After reexamination, claim 1 of the '913 Patent, the broadest and only independent claim recites:

1. A replicating in vitro cell culture of pluripotent human embryonic stem cells derived from a pre-implantation embryo, wherein the stem cells (i) will proliferate in an in vitro culture for over one year in an undifferentiated state without the application of exogenous leukemia inhibitory factor, (ii) maintain a karyotype in which the chromosomes are euploid through prolonged culture, (iii) maintain the potential to differentiate to derivatives of endoderm, mesoderm, and ectoderm tissues throughout the culture, (iv) are inhibited from differentiation when cultured on a fibroblast feeder layer.

Patent-Eligibility of hESCs

CW did not challenge the patent-eligibility of in vitro cultured hESCs in the reexamination proceeding but raises this argument for the first time in this appeal. CW argues that patent-eligibility is a threshold issue to be addressed before subordinate questions such as those related to anticipation and obviousness, citing Alexsam, Inc. v. IDT Corp., 2013 U.S. App. LEXIS 10009, at 30 (Fed. Cir. May 20, 2013)(Mayer, J. dissenting) and U.S. Nat'l Bank v. Indep. Ins. Agents, 508 U.S. 439, 447 (1993). Thus, CW argues that raising the issue of patent-eligibility at this stage is appropriate.

Although the '913 Patent expressly recites that the claimed hESCs are an in vitro culture, CW argues that the express limitation of the claims "merely identify properties that are inherent in all ES cells, including those that exist naturally." CW Brief at page 15. CW opines that, "if the claimed ES cells were not the same as natural ES cells, the claimed invention would offer very little benefit for medical research." Id. CW also argues that similar to the facts of Myriad, the '913 Patent claims recite neither a method of preparation nor a scientific application of the claimed composition, and that therefore, the claims are directed to a patent-ineligible product of nature. CW further contends that the '913 Patent claims do not distinguish the claimed hESCs from those that exist in nature and that the patentee "did not create or alter the properties inherent in stem cells any more than Myriad created or altered the genetic information encoded in the DNA it claimed." Id.

Anticipation and Obviousness

CW also challenges the Board's determination that the '913 Patent claims at issue were novel under 35 U.S.C. § 102. In the proceeding below, the Board held that the cited prior art (U.S. Patent No. 5,166,065, issued November 24, 1992 "Williams") did not teach the use of feeder cells to isolate embryonic stem cells. CW disagreed with the Board's interpretation that Williams only taught the use of feeder cells to maintain ES cells, but not to derive them.

CW also argues that no innovation was required to isolate the hESCs and that therefore, the claims are invalid for failing to satisfy 35 U.S.C. § 103 (non-obviousness). In arguing obviousness of the claims, CW challenges the expert opinion of Dr. Steward who declared that the morphology of hESCs are different from prior art mouse ES cell colonies. In the reexamination proceeding, Dr. Stewart had submitted a declaration noting that hESCs colonies are flatter and more compact than mouse ES cell colonies and that therefore, colonies of hESCs had not been described before the invention of the '913 Patent. CW urges the Federal Circuit not to rely on the testimony of Dr. Stewart but rather to rely on the teachings of other cited prior art that describes the isolation of mouse embryonic stem cells to guide the ordinary skilled scientist to test different colony types for features common to embryonic stem cells.

CW also urges the Federal Circuit to disregard secondary evidence of non-obviousness presented in the reexamination proceeding. In particular, CW asks the Federal Circuit to disregard evidence that others in the field had followed inventor Thomson's work to isolate hESCs and to disregard the acclaim Dr. Thomson has received in the field for his patented invention.

Cultured hESCs - Nonnatural Composition of Matter?

In its recent Myriad decision, the US Supreme Court held that isolated, naturally-occurring genes are not patent-eligible under 35 U.S.C. § 101 because isolated genes are a product of nature. The Myriad Court distinguished the facts and holding from a prior Supreme Court's decision, Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980). In Chakrabarty, the Supreme Court had previously held that genetically modified bacterium was patent-eligible. The Myriad Court distinguished the claimed isolated, natural-occurring genes from the subject of the Chakrabarty case, wherein the Court had held that the inventors had created a patentable, new composition of matter when they added four plasmids to a bacterium, which enabled it to break down various components of crude oil. Myriad, Slip Op. at 12, citing Chakrabarty, 447 U. S. at 305, and n. 1. The Myriad Court explained that the claimed genetically modified bacterium was "not to a hitherto unknown natural phenomenon, but to a nonnaturally occurring manufacture or composition of matter—a product of human ingenuity 'having a distinctive name, character [and] use.'" Id., citing Chakrabarty, at 309–310. The Chakrabarty bacterium was new "with markedly different characteristics from any found in nature," 447 U. S., at 310, due to the additional plasmids and resultant "capacity for degrading oil." Id., citing Chakrabarty, at 305, n. 1. The Court in Myriad held that in contrast, "Myriad did not create anything. To be sure, it found an important and useful gene, but separating that gene from its surrounding genetic material is not an act of invention." Myriad, Slip Op. at 12. The Court in Myriad also determined, however, that unlike isolated, naturally-occurring genes, man-made cDNA was patent-eligible because "the lab technician unquestionably creates something new when cDNA is made." Myriad, Slip Op. at 17.

Thus, the question for the Federal Circuit in this case is whether the claimed, cultured hESCs are markedly different from naturally-occurring hESCs. Does the process of culturing the cells provide the cells with "with markedly different characteristics from any found in nature?" Or, put differently, are hESCs more like patent-eligible man-made genes or more like patent-ineligible isolated, naturally-occurring genes?

Many in the biotech community were relieved that the Supreme Court in Myriad limited its holding of patent-ineligibility to isolated, naturally-occurring genes. However, patent practitioners cautioned that Myriad's holding could potentially be applied to other isolated, naturally-occurring products, including stem cells. The WARF case is likely the first test case before the Federal Circuit, and perhaps the U.S. Supreme Court ultimately, to define the reach and impact of Myriad beyond gene patents.

A copy of CW's Brief is attached. Appellee WARF's brief is due August 15, 2013.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
Foley & Lardner
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Foley & Lardner
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions